

**Anti-Spike RBD Reference Antibody (Casirivimab)  
Recombinant Antibody  
Catalog # APR10007****Specification**

---

**Anti-Spike RBD Reference Antibody (Casirivimab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">NA</a>
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.24 KDa


**Anti-Spike RBD Reference Antibody (Casirivimab) - Additional Information****Target/Specificity**  
Spike RBD**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.**Anti-Spike RBD Reference Antibody (Casirivimab) - Protein Information****Anti-Spike RBD Reference Antibody (Casirivimab) - Protocols**

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)

- [Flow Cytometry](#)
- [Cell Culture](#)


### Anti-Spike RBD Reference Antibody (Casirivimab) - Images



Anti-Spike RBD Reference Antibody (Casirivimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Spike RBD Reference Antibody (Casirivimab) is more than 99.84% ,determined by SEC-HPLC.



Immobilized 2019nCoV RBD His at 2 µg/mL can bind Anti-Spike RBD Reference Antibody (Casirivimab) □EC<sub>50</sub>=0.006201 µg/mL.